You are here
More People Can Receive Smallpox Vaccine in an Emergency
The U.S. government currently stockpiles enough traditional smallpox vaccine to protect the entire American population in the event of a smallpox bioterrorism attack. However, these replicating vaccines may cause severe complications for people with compromised immune systems or AD. Imvamune is being developed as an alternative for these individuals.
In its 2010 Broad Agency Announcement for Medical Countermeasure Development, the Biomedical Advanced Research and Development Authority (BARDA) noted the need for a sufficient quantity of attenuated smallpox vaccine to protect 28 million people with AD, 10 million people with compromised immune systems, and their household contacts––totaling 66 million people.
To date, the government has ordered 20 million doses of Imvamune to protect the 10 million people with immune deficiencies, in particular HIV infection. Bavarian Nordic expects to complete delivery of these vaccine doses by 2013.